Research Solutions, Inc. (NASDAQ:RSSS) issued a press release on November 11, 2026, announcing what the company described as the largest deal in its history: a $1 million enterprise Scite agreement with a Fortune 500 biopharmaceutical company.

Key Highlights

  • Largest deal in company history: The agreement is valued at $1 million with a Fortune 500 biopharmaceutical company, according to the filing.
  • Product coverage: The agreement covers an enterprise rollout of the Scite platform, full Scite API access, and additional Scite datasets, the company disclosed.
  • Expanded relationship: The customer had an existing Article Galaxy relationship with Research Solutions; the new agreement extends that with a full enterprise deployment of Scite across all of its research groups.
  • Evaluation process: The agreement followed a months-long enterprise evaluation that included live demonstrations, a technical trial, and reviews by procurement, legal, information security, technical architecture, and the customer's AI governance function, culminating in executive approval.
  • CEO statement: Roy W. Olivier, President and Chief Executive Officer, stated: "This agreement is the largest in our history, and it is not a one-off."

Research Solutions Announces $1 Million Enterprise Scite Agreement

According to the press release filed November 11, 2026, Research Solutions announced the signing of a $1 million enterprise agreement for its Scite platform with a Fortune 500 biopharmaceutical company. The company characterized the deal as the largest in its history. The customer had an existing Article Galaxy relationship with Research Solutions, and the new agreement expands that engagement with a full enterprise deployment of Scite across all of the customer's research groups.

The filing states that the agreement grants the customer's researchers and internal tools access to Scite's Smart Citations and scientific literature search capabilities. Specifically, the company disclosed that the agreement covers an enterprise rollout of the Scite platform, full Scite API access, and additional Scite datasets. These products are described in the filing as allowing the organization's internal tools "to search and evaluate peer-reviewed literature, cite the evidence behind an answer, check the veracity of claims, and retrieve licensed full text through existing entitlements within the workflows the organization already runs."

The company noted that the agreement followed a months-long enterprise evaluation process involving multiple departments and culminating in executive approval. In the filing, CEO Roy W. Olivier attributed the deal to broader demand, stating: "Every large R&D organization we talk to is rebuilding their search and discovery tools, and every one of them has the same problem: their AI agents need trusted access to the scientific literature." The filing notes that statements regarding customer demand, the company's pipeline, and expected adoption of its AI products are forward-looking and subject to risks and uncertainties described in the company's most recent annual report on Form 10-K and subsequent filings with the Securities and Exchange Commission.

What Was Disclosed

Research Solutions disclosed a $1 million enterprise Scite agreement with a Fortune 500 biopharmaceutical company, described as the largest deal in company history, covering full platform deployment, API access, and additional datasets for the customer's research and AI workflows.